AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6391495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31552831 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal pertussis vaccination within the first three postpartum days
Number of subjects: 405
Study 31552831 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated mothers
Number of subjects: 405
Study 30025255 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 83
Study 30025255 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive-Behavioral Therapy (GCBT)
Number of subjects: 83
Study 30025255 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (FLX) and GCBT
Number of subjects: 83
Study 26223239 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate lifestyle intervention including individualized counseling on diet, physical activity, and weight control; one group meeting with a dietitian.
Number of subjects: 293
Study 26223239 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (control group).
Number of subjects: 293
Study 26223239 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate lifestyle intervention.
Number of subjects: 293
Study 23078583 — intervention group
Group type: EXPERIMENTAL
Intervention: B-BAES (6-item Brief Biphasic Alcohol Effects Scale)
Number of subjects: 104
Study 23078583 — intervention group
Group type: EXPERIMENTAL
Intervention: B-BAES
Number of subjects: 104
Study 21440878 — intervention group
Group type: COMPARATOR
Intervention: Traditional Acupuncture (TA)
Number of subjects: 49
Study 21440878 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Acupuncture (CA)
Number of subjects: 49
Study 19426180 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils-containing mouthrinse
Number of subjects: 50
Study 19426180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16766781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal (acidogenic) foods
Number of subjects: 40
Study 16766781 — intervention group
Group type: COMPARATOR
Intervention: Fruit and vegetable (alkalinogenic) foods
Number of subjects: 40
Study 15532669 — intervention group
Group type: EXPERIMENTAL
Intervention: Word training (training to identify the number of moras in Japanese words spoken in isolation)
Number of subjects: 0
Study 15532669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence training (training to identify the number of moras in Japanese words spoken in sentences)
Number of subjects: 0
Study 15532669 — intervention group
Group type: COMPARATOR
Intervention: Untrained control group
Number of subjects: 0
Study 15532669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence training
Number of subjects: 0
Study 11518201 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine enriched with 1.5 g/d plant sterols
Number of subjects: 155
Study 11518201 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine enriched with 3.0 g/d plant sterols
Number of subjects: 155
Study 11518201 — intervention group
Group type: COMPARATOR
Intervention: Control spread (rapeseed oil-based)
Number of subjects: 155
Study 9289524 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic brief advice with support material and a five visit program during a year
Number of subjects: 139
Study 9289524 — intervention group
Group type: COMPARATOR
Intervention: Once brief advice and a control in 1 year
Number of subjects: 139
Study 7687364 — intervention group
Group type: EXPERIMENTAL
Intervention: DSG low dose
Number of subjects: 200
Study 7687364 — intervention group
Group type: EXPERIMENTAL
Intervention: DSG high dose
Number of subjects: 200
Study 7687364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 3814446 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing for 12 hours
Number of subjects: 16
Study 3814446 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pacing)
Number of subjects: 16
Study 29131699 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) evaluated by polymerase chain reaction analysis of Ig/TCR gene rearrangements
Number of subjects: 3113
Study 29131699 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk genetics and T-cell acute lymphoblastic leukemia
Number of subjects: 3113
Study 29131699 — intervention group
Group type: EXPERIMENTAL
Intervention: Each log reduction in disease level
Number of subjects: 3113
Study 29131699 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of genetic subtype-specific MRD values
Number of subjects: 3113
Study 27615048 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Program (SMP)
Number of subjects: 40
Study 24504100 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg IV every 3 months for 24 months)
Number of subjects: 70
Study 24504100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24504100 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 70
Study 22854323 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 161
Study 22854323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 20071999 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 5 mg once daily
Number of subjects: 86
Study 20071999 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 10 mg once daily
Number of subjects: 86
Study 20071999 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 15 mg once daily
Number of subjects: 86
Study 20071999 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc (all doses)
Number of subjects: 86
Study 20071999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17888074 — intervention group
Group type: EXPERIMENTAL
Intervention: AED withdrawal
Number of subjects: 160
Study 17888074 — intervention group
Group type: COMPARATOR
Intervention: Nonwithdrawal (control)
Number of subjects: 160
Study 19497249 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg
Number of subjects: 90
Study 19497249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15892782 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning exemplars characterized by common function
Number of subjects: 98
Study 15892782 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning exemplars characterized by common appearance
Number of subjects: 98
Study 12366485 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 210
Study 12366485 — intervention group
Group type: COMPARATOR
Intervention: False acupuncture (control)
Number of subjects: 210
Study 9692101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation (21 min-1) during FOB and continued for 120 min after FOB in group 2.
Number of subjects: 34
Study 9692101 — intervention group
Group type: COMPARATOR
Intervention: No oxygen supplementation after FOB in group 1.
Number of subjects: 34
Study 7823546 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour hydration treatment
Number of subjects: 12
Study 7823546 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour dehydration treatment
Number of subjects: 12
Study 7823546 — intervention group
Group type: COMPARATOR
Intervention: 4-hour placebo (control) treatment
Number of subjects: 12
Study 3350160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal culture (IVC)
Number of subjects: 160
Study 11403534 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors
Number of subjects: 0
Study 11403534 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 0
Study 11403534 — intervention group
Group type: COMPARATOR
Intervention: Acid suppression
Number of subjects: 0
Study 31182528 — intervention group
Group type: COMPARATOR
Intervention: GSK3036656 single doses of 5 mg (fed and fasted), 15 mg, and 25 mg; placebo as control
Number of subjects: 0
Study 31182528 — intervention group
Group type: COMPARATOR
Intervention: GSK3036656 repeat doses of 5 mg and 15 mg; placebo as control
Number of subjects: 0
Study 31182528 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3036656 (both single and multiple doses)
Number of subjects: 0
Study 29077783 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue intervention (performing a stop-signal task for 90 minutes)
Number of subjects: 32
Study 29077783 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (watching a video for 90 minutes)
Number of subjects: 32
Study 27424014 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin (Group A)
Number of subjects: 190
Study 27424014 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem (Group B)
Number of subjects: 190
Study 27424014 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (Group C)
Number of subjects: 190
Study 24399268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored text messages
Number of subjects: 2030
Study 24399268 — intervention group
Group type: COMPARATOR
Intervention: Untailored text messages
Number of subjects: 2030
Study 24399268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored text messages (restricted analysis)
Number of subjects: 2030
Study 24399268 — intervention group
Group type: COMPARATOR
Intervention: Untailored text messages (restricted analysis)
Number of subjects: 2030
Study 23359967 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA combined with Compound Huangdai Tablet
Number of subjects: 83
Study 23359967 — intervention group
Group type: COMPARATOR
Intervention: ATRA combined with MTX + 6MP
Number of subjects: 83
Study 20028919 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (intermediate- versus low-dose)
Number of subjects: 37
Study 20028919 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tumor blood flow
Number of subjects: 37
Study 20028919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor blood flow and mean transit time (MTT) at follow-up
Number of subjects: 37
Study 17922014 — intervention group
Group type: EXPERIMENTAL
Intervention: HMMR locus
Number of subjects: 0
Study 17922014 — intervention group
Group type: EXPERIMENTAL
Intervention: Network modeling strategy
Number of subjects: 0
Study 16198089 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech discrimination training
Number of subjects: 17
Study 16198089 — intervention group
Group type: COMPARATOR
Intervention: Untrained control group
Number of subjects: 17
Study 11953279 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalative mucolytic drug mercapto‐ethane sulfonate (Mesna)
Number of subjects: 10
Study 11953279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10404292 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 69
Study 10404292 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 69
Study 10404292 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 8669222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg/kg (group A)
Number of subjects: 3
Study 8669222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.17 mg/kg (group B)
Number of subjects: 3
Study 8669222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.19 mg/kg (group C)
Number of subjects: 3
Study 8669222 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 3
Study 2161615 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% maltodextrin (6% M)
Number of subjects: 8
Study 2161615 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% glucose-fructose mix (6% GF)
Number of subjects: 8
Study 2161615 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% glucose-fructose mix (8% GF)
Number of subjects: 8
Study 2161615 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose-fructose mix (10% GF)
Number of subjects: 8
Study 2161615 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (W)
Number of subjects: 8
Study 271589 — intervention group
Group type: EXPERIMENTAL
Intervention: Roll technique
Number of subjects: 28
Study 271589 — intervention group
Group type: COMPARATOR
Intervention: Bass technique
Number of subjects: 28
Study 31511080 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with ambrisentan 10 mg plus tadalafil 40 mg
Number of subjects: 500
Study 31511080 — intervention group
Group type: COMPARATOR
Intervention: Pooled monotherapy (ambrisentan 10 mg plus placebo or tadalafil 40 mg plus placebo)
Number of subjects: 500
Study 28940368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (cerebral oximetry monitoring with algorithm activation if saturation < 75%)
Number of subjects: 249
Study 28940368 — intervention group
Group type: COMPARATOR
Intervention: Control group (cerebral oximetry monitor screen blinded)
Number of subjects: 249
Study 28940368 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline regional cerebral oxygen saturation ≤ 50%
Number of subjects: 249
Study 28940368 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline regional cerebral oxygen saturation > 50%
Number of subjects: 249
Study 26179177 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSAs) for 6 months
Number of subjects: 55
Study 26179177 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 55
Study 24633859 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 217
Study 24633859 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 217
Study 22539172 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group education programme for six hours delivered in the community by two trained healthcare professional educators
Number of subjects: 731
Study 22539172 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 731
Study 18759737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertiary individual prevention (TIP) - 3 weeks inpatient treatment including intensive health care instruction and psychological counseling, followed by outpatient treatment by the local dermatologist.
Number of subjects: 1000
Study 18759737 — intervention group
Group type: COMPARATOR
Intervention: Secondary individual prevention (SIP) - combined outpatient dermatologic and health-educational intervention seminars.
Number of subjects: 1000
Study 17121868 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airways Pressure (CPAP)
Number of subjects: 101
Study 17121868 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Appliance
Number of subjects: 101
Study 17121868 — intervention group
Group type: COMPARATOR
Intervention: Conservative Measures (sleep hygiene)
Number of subjects: 101
Study 15888698 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 695
Study 15888698 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 695
Study 15060873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketodiet (0.3 g/kg/d protein plus tablets of KAs)
Number of subjects: 34
Study 15060873 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.6 g/kg/d protein plus placebo)
Number of subjects: 34
Study 11552770 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine add on to haloperidol 5 mg
Number of subjects: 30
Study 11552770 — intervention group
Group type: COMPARATOR
Intervention: Placebo add on to haloperidol 5 mg
Number of subjects: 30
Study 9760358 — intervention group
Group type: EXPERIMENTAL
Intervention: DentinBloc cavity liner
Number of subjects: 16
Study 9760358 — intervention group
Group type: COMPARATOR
Intervention: Copalite cavity liner
Number of subjects: 16
Study 7936817 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath‐by‐breath alternations in fractional inspired oxygen concentration (0.21 and 0.16)
Number of subjects: 8
Study 3125882 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg aspirin daily
Number of subjects: 5139
Study 3125882 — intervention group
Group type: COMPARATOR
Intervention: Control group (not given a placebo)
Number of subjects: 5139
Study 29697508 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line filtration
Number of subjects: 268
Study 29697508 — intervention group
Group type: COMPARATOR
Intervention: No-filter (standard care)
Number of subjects: 268
Study 28242866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide (10 mg) and Voglibose (0.2 mg) (M+V) 3 times daily
Number of subjects: 5
Study 28242866 — intervention group
Group type: COMPARATOR
Intervention: Dipeptidyl Peptidase-4 Inhibitor (Linagliptin 5 mg) (L) once daily
Number of subjects: 5
Study 28242866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (M+V and L)
Number of subjects: 5
Study 24203489 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mindfulness
Number of subjects: 107
Study 24203489 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritualized mindfulness
Number of subjects: 107
Study 24203489 — intervention group
Group type: COMPARATOR
Intervention: Simple relaxation
Number of subjects: 107
Study 23292563 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon viewed 3D reconstruction before and during surgery
Number of subjects: 112
Study 23292563 — intervention group
Group type: COMPARATOR
Intervention: Surgeon viewed 3D reconstruction after surgery
Number of subjects: 112
Study 21553974 — intervention group
Group type: EXPERIMENTAL
Intervention: Question-behavior effect condition (completed questionnaire about health checks)
Number of subjects: 0
Study 21553974 — intervention group
Group type: EXPERIMENTAL
Intervention: Question-behavior effect condition (completed questionnaire about influenza vaccination)
Number of subjects: 0
Study 18974657 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic ointment (AO) prophylaxis
Number of subjects: 116
Study 18974657 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter antimicrobial locking (AL) with heparin + gentamicin (5.2 mg/ml)
Number of subjects: 116
Study 18974657 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AO and AL prophylaxis
Number of subjects: 116
Study 16957997 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical techniques or methods for hepatectomy
Number of subjects: 0
Study 16957997 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical techniques or methods for pancreatectomy
Number of subjects: 0
Study 16957997 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter studies on hepatectomy
Number of subjects: 0
Study 16957997 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of multicenter studies
Number of subjects: 0
Study 16957997 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate RCTs observing the Consolidated Standards of Reporting Trials statements
Number of subjects: 0
Study 12915429 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose guggulipid (1000 mg)
Number of subjects: 103
Study 12915429 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose guggulipid (2000 mg)
Number of subjects: 103
Study 12915429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 12915429 — intervention group
Group type: EXPERIMENTAL
Intervention: Guggulipid (both doses)
Number of subjects: 103
Study 12915429 — intervention group
Group type: EXPERIMENTAL
Intervention: Guggulipid
Number of subjects: 103
Study 10834782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziconotide 0.7 microg/h
Number of subjects: 30
Study 10834782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziconotide 7.0 microg/h
Number of subjects: 30
Study 10834782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10163305 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to chemical hazards
Number of subjects: 1841
Study 10163305 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about exposure to chemical hazards
Number of subjects: 1841
Study 1539474 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg.kg‐1
Number of subjects: 30
Study 1539474 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 4.5 mg.kg‐1
Number of subjects: 30
Study 3886394 — intervention group
Group type: EXPERIMENTAL
Intervention: Binedaline 100 mg (females) and 150 mg (males)
Number of subjects: 0
Study 3886394 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 50 mg and 75 mg
Number of subjects: 0
Study 3886394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3886394 — intervention group
Group type: EXPERIMENTAL
Intervention: Binedaline
Number of subjects: 0
Study 3886394 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 3886394 — intervention group
Group type: EXPERIMENTAL
Intervention: Binedaline and Amitriptyline
Number of subjects: 0
Study 29457317 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol infusion (0.08% blood alcohol level)
Number of subjects: 54
Study 29457317 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 54
Study 29692566 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading protocol (Group I)
Number of subjects: 20
Study 29692566 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading protocol (Group II)
Number of subjects: 20
Study 29692566 — intervention group
Group type: COMPARATOR
Intervention: Comparison of immediate loading to delayed loading protocol
Number of subjects: 20
Study 27416664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg qd
Number of subjects: 116
Study 27416664 — intervention group
Group type: COMPARATOR
Intervention: Control (Tamsulosin 20 mg qd)
Number of subjects: 116
Study 23606682 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA therapy (prednisolone 60 mg/day, tapered to 7.5 mg/day in 6 weeks, methotrexate 7.5 mg/week, sulfasalazine 2 g/day)
Number of subjects: 164
Study 23606682 — intervention group
Group type: COMPARATOR
Intervention: COBRA-light therapy (lower dose prednisolone starting at 30 mg/day, tapered to 7.5 mg/day in 9 weeks, methotrexate escalated to 25 mg/week in 9 weeks)
Number of subjects: 164
Study 21896540 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM + ET (gemcitabine plus cationic liposomal paclitaxel)
Number of subjects: 200
Study 21896540 — intervention group
Group type: COMPARATOR
Intervention: GEM (gemcitabine alone)
Number of subjects: 200
Study 19399887 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmid VEGF
Number of subjects: 50
Study 19399887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50